Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 3, 2006, Pages 133-139

  Itoh, Kunio ^a   Yamamura, Mayumi ^b   Takasaki, Wataru ^b   Sasaki, Takamitsu ^a   Masubuchi, Akiko ^a   Tanaka, Yorihisa ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Aldehyde oxidase; Enantioselectivity; MAO A inhibitor; RS 8359; Species differences

Indexed keywords

4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; ALDEHYDE OXIDASE; ALKALOID; CINCHONA ALKALOID; CINCHONIDINE SULFATE; CINCHONINE SULFATE; DRUG METABOLITE; HYDROXYL GROUP; MONOAMINE OXIDASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG OXIDATION; DRUG SELECTIVITY; DRUG STRUCTURE; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME ACTIVE SITE; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CYTOSOL; MALE; MONKEY; MOUSE; NONHUMAN; RABBIT; RACEMIC MIXTURE; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPECIES DIFFERENCE;

ALDEHYDE OXIDASE; ANIMALS; CINCHONA ALKALOIDS; CYTOSOL; DOGS; GUINEA PIGS; HUMANS; KETO ACIDS; LIVER; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED STRAINS; MONOAMINE OXIDASE INHIBITORS; NITRILES; OXIDATION-REDUCTION; PYRIMIDINES; RABBITS; RATS; RATS, WISTAR; SPECIES SPECIFICITY; STEREOISOMERISM;

EID: 33646356964     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.494     Document Type: Article

References (25)

1. Yokoyama T, Karube T, Iwata N. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. J Pharm Pharmacol 1989; 41: 32-36.
2. Kumagae Y, Matsui Y, Iwata N. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 1991; 55: 121-128.
3. Miura H, Naoi M, Nakahara D, Ohta T, Nagatsu T. Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359. J Neural Transm 1993; 94: 175-187.
4. Iwata N, Tonohiro T, Kozuka M, Kumagae Y, Takasaki W, Tanaka Y. A novel selective and reversible MAO-A inhibitor, RS-8359: its pharmacological properties and metabolism. Int Acad Biomed Drug Res 1996; 11: 285-286.
5. Puchler K, Schaffler K, Plenker A. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. Int Clin Psychopharm 1997; 12: S17-S23.
6. Plenker A, Puchler K, Volz HP. The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. Int Clin Psychopharm 1997; 12: S25-S29.
7. Iwabuchi H, Takasaki W, Kuwano H, Kobayashi T, Tanaka Y. Structural determination of rat and dog urinary metabolites of a new antidepressant RS-8359. Xenobio Metab Dispos 1998; 13: 351-361.
8. Takasaki W, Yamamura M, Nozaki A, et al. Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug metabolizing enzymes. Chirality 2005; 17: 135-141.
9. Itoh K, Yamamura M, Muramatsu S, et al. Stereospecific oxidation of the (S)-enantiomer of RS-8359, a selective and reversible monoamine oxidase A (MAO-A) inhibitor, by aldehyde oxidase. Xenobiotica 2005; 35: 561-573.
10. 2-dependent type. J Biol Chem 1995; 265: 14170-14175.
11. LiCalzi ML, Raviolo C, Ghibaudi E, et al. Purification, cDNA cloning and tissue distribution of bovine liver aldehyde oxidase. J Biol Chem 1995; 270: 31037-31045.
12. Beedham C. Molybdenum Hydroxylases. In Enzyme Systems that Metabolize Drugs and Other Xenobiotics, Ioannides C (ed.). John Wiley & Sons Ltd: UK, 2002; 147-187.
13. Jordan CGM, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C. Aldehyde oxidase-catalyzed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol 1999; 51: 411-418.
14. Keuzenkamplansen CW, vanBaal JM, DeAbeu R, deJong JGN, Zuiderent T, Trilbels JMF. Detection and identification of 6-methylmercapto-8-hydroxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration. Clin Chem 1996; 42: 380-386.
15. Beedham C, Al-Tayib Y, Smith JA. The role of guinea pig and rabbit hepatic aldehyde oxidase in the oxidative in vitro metabolism of cinchona alkaloids. Drug Metab Dispos 1992; 20: 889-895.
16. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver. Drug Metab Dispos 1997; 25: 805-813.
17. Kitamura K, Tatsumi K. Reduction of tertiary amine N-oxides by liver preparations: Function of aldehyde oxidase as a major N-oxide reductase. Biochem Biophys Res Commun 1984; 121: 749-754.
18. Sugihara K, Kitamura S, Tatsumi K. S-(-)-Nicotine-1′-oxide reductase activity of rat liver aldehyde oxidase. Biochem Mol Biol Inter 1996; 40: 535-541.
19. Tatsumi K, Kitamura S, Yamada H. Involvement of liver aldehyde oxidase in sulfoxide reduction. Chem Pharm Bull 1982; 12: 4585-4588.
20. Beedham C. Molybdenum hydroxylases as drug metabolizing enzymes. Drug Metab Rev 1985; 16: 119-156.
21. Beedham C. Molybdenum hydroxylases: biological distribution and substrate- inhibitor specificity. In Progress in Medicinal Chemistry, Vol. 24, Ellis GP, West GB (eds). Elsevier Science Publishers: Amsterdam, 1987; 85-127.
22. Beedham C, Bruce SE, Critchley DJ, Al-Tayib Y, Rance DJ. Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokin 1987; 12: 307-310.
23. Acheampong AA, Chien D-S, Lam S, et al. Characterization of brominidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 1996; 26: 1035-1055.
24. Chaudhary I, DeMaio W, Kantrowitz J. Species comparison of in vitro and in vivo metabolism of CL284, 846, a non-benzodiazepine sedative/hypnotic agent. Pharm Res 1994; 11: 319.
25. Kitamura S, Sugihara K, Nakatani K, et al. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 1999; 48: 607-611.